CustomCells strengthens its commitment in eAviation
mehr
Ergebnis der Suchanfrage nach Tübingen
Inhalte
- Kategorie:
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
31 Treffer
CustomCells founds U.S. subsidiary with Detroit site
mehrHearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy ...
mehrAcousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease
Tübingen (ots) - - German pioneer biotech accelerates hearing loss solution development with fresh capital boost Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors. The infusion of fresh ...
mehrTechnische Universität München
Prof. Pfleiderer new scientific director of the FRM II
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Change at the top of the TUM Research Neutron Source Prof. Pfleiderer new scientific director of the FRM II • Experimental physicist with an international reputation • Manager with scientific vision and diplomatic skills • FRM II as a service provider for researchers in Germany and abroad The Heinz Maier-Leibnitz Research Neutron Source (FRM II) is getting a new ...
mehrEnergy at its best: German battery pioneer CustomCells unveils new brand identity
mehrPress Release: Instone sells 105 predominantly subsidized apartments in the "Neckar.Au Viertel" to the city of Rottenburg am Neckar
Ein DokumentmehrHearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots/PRNewswire) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic ...
mehrHearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ...
mehrHearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September
Tübingen, Germany (ots) - Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations at industry and research meetings from August 29 to September 5. From August 29–31, Acousia ...
mehrAnother step towards electrified aviation: CustomCells enters cooperation with VÆRIDION
mehrCustomcells launches development partnership with OneD
mehrProject TwinTrace: Customcells works together with partners on a smart battery factory
mehrCustomcells strengthens sustainable battery industry ‘Made in Germany’
mehrTechnische Universität München
Position paper: “ChatGPT can lead to greater equity in education”
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Position paper outlines opportunities for schools and universities “ChatGPT can lead to greater equity in education” • Interdisciplinary position paper on opportunities and risks of language models in education • Personalized use of applications could bring about individual improvement for learners • Artificial ...
mehrHearing loss company Acousia Therapeutics completes clinical Phase 1 study with its small molecule
Tübingen, Germany (ots) - Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last patient treated with the highest ACOU085 dose. ACOU085 is a proprietary small-molecule drug candidate under clinical ...
mehrGerman battery pioneer closes Series A financing round: 60 million euros for Customcells
mehrHearing loss company Acousia Therapeutics to present data for lead candidates ACOU085 & ACOU082 at ARO 2023 MidWinter Meeting February 11–15
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, and its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and Neck Surgery, University of Tübingen), will present data on its lead candidates — clinical stage ACOU085 and late ...
mehrCUSTOMCELLS publishes future theses for Germany's battery industry
mehrCellforce Group lays foundation for modern, sustainable battery production in Europe
mehr10 years of CUSTOMCELLS: Battery cell specialist ready for the next phase of growth
mehrBattery innovator's new CEO / Dirk Abendroth joins CUSTOMCELLS' Board of Management
mehrThe year of battery cell technology: CUSTOMCELLS expects massive growth in 2022
mehrCUSTOMCELLS brings three new shareholders on board following funding round
mehrCellforce Group GmbH: Joint Venture between Porsche and CUSTOMCELLS
mehrTechnische Universität München
Video-link added - Breakthrough in nuclear physics: High-precision measurements of the strong interaction between stable and unstable particles
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36351/ High resolution images: https://cds.cern.ch/record/2746022 – ...
mehrTechnische Universität München
Breakthrough in nuclear physics: High-precision measurements of the strong interaction between stable and unstable particles
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36351/ High resolution images: https://cds.cern.ch/record/2746022 – ...
mehrTechnische Universität München
A molecular map for the plant sciences
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161/ 71-5403 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/ High resolution images: https://mediatum.ub.tum.de/1540641 NEWS RELEASE First comprehensive map of the proteome of the model plant Arabidopsis thaliana A molecular map for the plant sciences Plants are essential for ...
mehrTechnische Universität München
The GERDA-Collaboration: Major steps forward in understanding neutrino properties
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: http://www.tum.de/nc/die-tum/aktuelles/pressemitteilungen/details/35672/ High resolution images: https://mediatum.ub.tum.de/1518985 NEWS RELEASE Closing in on elusive particles Major steps forward in understanding ...
mehrCutting-edge technology for emergencies from Germany: A3M and F24 start a close collaboration so that customers can benefit from an integrated product for early crisiswarning, alerting and crisis management
Munich (ots) - A3M and F24, two of the leading European companies in crisis early warning, alerting and crisis management systems, now offer an integrated solution. The essential factor of the new collaboration: F24, the European market leader in the field of alerting, crisis management and critical business ...
mehr
12Nächste